Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases

Aim:  Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that...

Full description

Saved in:
Bibliographic Details
Published inNephrology (Carlton, Vic.) Vol. 11; no. 5; pp. 381 - 385
Main Authors SIMPSON, IAN J, MARSHALL, MARK R, PILMORE, HELEN, MANLEY, PAUL, WILLIAMS, LAURIE, THEIN, HLA, VOSS, DAVID
Format Journal Article
LanguageEnglish
Published Melbourne, Australia Blackwell Publishing Asia 01.10.2006
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim:  Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that were referred to renal services in Auckland over a period of 3 years. Methods:  The clinical presentation, therapeutic drugs, demographic details and renal outcome of the patients were considered. The population at risk and total PPI exposure were able to be defined. The diagnosis of AIN was made by renal biopsy in 12 cases. In all patients, the time‐course of drug exposure and improvement of renal function on withdrawal suggested PPI were causal. Results:  The median patient age was 78 years. The mean baseline serum creatinine level was 83 µmol/L, peak level 392 µmol/L, and recovery level 139 µmol/L. The erythrocyte sedimentation rate (ESR) and C‐reactive protein were elevated at the time of diagnosis in the 11 and 12 patients, respectively, where this information was collected (ESR mean 85 mm/h, and C‐reactive protein mean 81 mg/L). AIN occurred at 8 per 100 000 patient years (95% confidence level 2.6–18.7 per 100 000 patient years). Although four patients presented with an acute systemic allergic reaction, 11 were asymptomatic with an insidious development of renal failure. Conclusion:  PPI are now the most commonly identified cause of AIN in the Auckland area. Recovery occurs after withdrawal of the drug but is often incomplete. Early diagnosis may be facilitated by clinician awareness of the insidious onset of renal failure, and an elevated erythrocyte sedimentation rate and C‐reactive protein.
AbstractList Aim:  Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that were referred to renal services in Auckland over a period of 3 years. Methods:  The clinical presentation, therapeutic drugs, demographic details and renal outcome of the patients were considered. The population at risk and total PPI exposure were able to be defined. The diagnosis of AIN was made by renal biopsy in 12 cases. In all patients, the time‐course of drug exposure and improvement of renal function on withdrawal suggested PPI were causal. Results:  The median patient age was 78 years. The mean baseline serum creatinine level was 83 µmol/L, peak level 392 µmol/L, and recovery level 139 µmol/L. The erythrocyte sedimentation rate (ESR) and C‐reactive protein were elevated at the time of diagnosis in the 11 and 12 patients, respectively, where this information was collected (ESR mean 85 mm/h, and C‐reactive protein mean 81 mg/L). AIN occurred at 8 per 100 000 patient years (95% confidence level 2.6–18.7 per 100 000 patient years). Although four patients presented with an acute systemic allergic reaction, 11 were asymptomatic with an insidious development of renal failure. Conclusion:  PPI are now the most commonly identified cause of AIN in the Auckland area. Recovery occurs after withdrawal of the drug but is often incomplete. Early diagnosis may be facilitated by clinician awareness of the insidious onset of renal failure, and an elevated erythrocyte sedimentation rate and C‐reactive protein.
Aim:  Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that were referred to renal services in Auckland over a period of 3 years. Methods:  The clinical presentation, therapeutic drugs, demographic details and renal outcome of the patients were considered. The population at risk and total PPI exposure were able to be defined. The diagnosis of AIN was made by renal biopsy in 12 cases. In all patients, the time‐course of drug exposure and improvement of renal function on withdrawal suggested PPI were causal. Results:  The median patient age was 78 years. The mean baseline serum creatinine level was 83 µmol/L, peak level 392 µmol/L, and recovery level 139 µmol/L. The erythrocyte sedimentation rate (ESR) and C‐reactive protein were elevated at the time of diagnosis in the 11 and 12 patients, respectively, where this information was collected (ESR mean 85 mm/h, and C‐reactive protein mean 81 mg/L). AIN occurred at 8 per 100 000 patient years (95% confidence level 2.6–18.7 per 100 000 patient years). Although four patients presented with an acute systemic allergic reaction, 11 were asymptomatic with an insidious development of renal failure. Conclusion:  PPI are now the most commonly identified cause of AIN in the Auckland area. Recovery occurs after withdrawal of the drug but is often incomplete. Early diagnosis may be facilitated by clinician awareness of the insidious onset of renal failure, and an elevated erythrocyte sedimentation rate and C‐reactive protein.
Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that were referred to renal services in Auckland over a period of 3 years. The clinical presentation, therapeutic drugs, demographic details and renal outcome of the patients were considered. The population at risk and total PPI exposure were able to be defined. The diagnosis of AIN was made by renal biopsy in 12 cases. In all patients, the time-course of drug exposure and improvement of renal function on withdrawal suggested PPI were causal. The median patient age was 78 years. The mean baseline serum creatinine level was 83 micromol/L, peak level 392 micromol/L, and recovery level 139 micromol/L. The erythrocyte sedimentation rate (ESR) and C-reactive protein were elevated at the time of diagnosis in the 11 and 12 patients, respectively, where this information was collected (ESR mean 85 mm/h, and C-reactive protein mean 81 mg/L). AIN occurred at 8 per 100 000 patient years (95% confidence level 2.6-18.7 per 100 000 patient years). Although four patients presented with an acute systemic allergic reaction, 11 were asymptomatic with an insidious development of renal failure. PPI are now the most commonly identified cause of AIN in the Auckland area. Recovery occurs after withdrawal of the drug but is often incomplete. Early diagnosis may be facilitated by clinician awareness of the insidious onset of renal failure, and an elevated erythrocyte sedimentation rate and C-reactive protein.
Author PILMORE, HELEN
SIMPSON, IAN J
THEIN, HLA
MANLEY, PAUL
WILLIAMS, LAURIE
MARSHALL, MARK R
VOSS, DAVID
Author_xml – sequence: 1
  givenname: IAN J
  surname: SIMPSON
  fullname: SIMPSON, IAN J
  email: i.simpson@auckland.ac.nz
  organization: Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland
– sequence: 2
  givenname: MARK R
  surname: MARSHALL
  fullname: MARSHALL, MARK R
  organization: Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland
– sequence: 3
  givenname: HELEN
  surname: PILMORE
  fullname: PILMORE, HELEN
  organization: Renal Service, Auckland City Hospital, and
– sequence: 4
  givenname: PAUL
  surname: MANLEY
  fullname: MANLEY, PAUL
  organization: Renal Service, Auckland City Hospital, and
– sequence: 5
  givenname: LAURIE
  surname: WILLIAMS
  fullname: WILLIAMS, LAURIE
  organization: Renal Service, Auckland City Hospital, and
– sequence: 6
  givenname: HLA
  surname: THEIN
  fullname: THEIN, HLA
  organization: Renal Service, Auckland City Hospital, and
– sequence: 7
  givenname: DAVID
  surname: VOSS
  fullname: VOSS, DAVID
  organization: Department of Renal Medicine, Middlemore Hospital, Auckland, New Zealand
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17014549$$D View this record in MEDLINE/PubMed
BookMark eNqNkF1PwjAUhhuDkQ_9C6Z_YLPt2n0YbwxBNCFICEbumtKdhSJsSzsi_HuLI3hrk5O-ad_nXDx91CmrEhDClITUn4dNSDknAU2yJGSExKEfQcPDFepdPjo-R4wEIhJpF_Wd2xBCExbTG9SlCaFc8KyHljNbNVWJ6_2uxqZcm5VpKuuwKnOs9L4B_9iAdY1pjNriEuq19dE94jnUlW3aYqm2R2ccrgpMBdbKgbtF14XaOrg73wP08TJaDF-Dyfv4bfg8CTTPBA24EDGkWhGSc5IziHXKeMYpzUjGWMa0zmlRABF8FTOt_KRFSgA00CLhGqIBStu92lbOWShkbc1O2aOkRJ5kyY08OZEnJ_IkS_7KkgeP3rdovV_tIP8Dz3Z84aktfJstHP-9WE5HMx88HrS4cQ0cLriyXzJOokTIz-lYLuZLFsXDpcyiH993iXM
CitedBy_id crossref_primary_10_1186_s12882_016_0325_4
crossref_primary_10_1186_s12882_018_0848_y
crossref_primary_10_1093_ndt_gfw470
crossref_primary_10_1590_2175_8239_jbn_2018_0021
crossref_primary_10_1186_s12882_017_0536_3
crossref_primary_10_1038_ki_2014_294
crossref_primary_10_3390_jcm12072467
crossref_primary_10_1093_ckj_sfad109
crossref_primary_10_1016_j_nephro_2017_06_005
crossref_primary_10_1016_j_amjms_2021_05_017
crossref_primary_10_1016_j_techsoc_2012_06_002
crossref_primary_10_1038_s41581_024_00854_w
crossref_primary_10_1093_ndtplus_sfq146
crossref_primary_10_1097_MJT_0b013e31817149bf
crossref_primary_10_1007_s13730_015_0204_z
crossref_primary_10_1080_17425255_2018_1539076
crossref_primary_10_1111_j_1365_2125_2007_02927_x
crossref_primary_10_1097_MJT_0000000000001368
crossref_primary_10_33667_2078_5631_2024_5_36_42
crossref_primary_10_1053_j_ajkd_2018_04_013
crossref_primary_10_1186_s40545_019_0167_0
crossref_primary_10_7759_cureus_49883
crossref_primary_10_1111_fcp_12451
crossref_primary_10_3390_jcm11164786
crossref_primary_10_1053_j_gastro_2010_08_023
crossref_primary_10_1136_bmjopen_2020_047059
crossref_primary_10_1016_j_cld_2014_05_003
crossref_primary_10_1517_14740330802410462
crossref_primary_10_1093_ndt_gfaa169
crossref_primary_10_1053_j_ajkd_2015_10_030
crossref_primary_10_1016_j_lpm_2012_09_016
crossref_primary_10_1097_MAJ_0000000000000323
crossref_primary_10_1097_MCG_0000000000001035
crossref_primary_10_2478_inmed_2020_0127
crossref_primary_10_1016_j_ekir_2017_01_005
crossref_primary_10_1038_ki_2014_74
crossref_primary_10_1177_2042098617715381
crossref_primary_10_15171_PS_2016_30
crossref_primary_10_1111_j_1365_2036_2007_03407_x
crossref_primary_10_1016_j_biopha_2023_115149
crossref_primary_10_17533_udea_iatreia_45
crossref_primary_10_1053_j_ajkd_2014_04_027
crossref_primary_10_1007_s40266_014_0166_4
crossref_primary_10_1053_j_gastro_2008_08_044
crossref_primary_10_1186_s12882_020_02175_z
crossref_primary_10_4081_cp_2018_1065
crossref_primary_10_1093_ndt_gfp751
crossref_primary_10_2215_CJN_11290821
crossref_primary_10_1007_s11033_023_08573_4
crossref_primary_10_1111_j_1440_1797_2006_00675_x
crossref_primary_10_21763_tjfmpc_698985
crossref_primary_10_1681_nsap_2022_21_1_5
crossref_primary_10_5124_jkma_2020_63_1_30
crossref_primary_10_5858_133_2_268
crossref_primary_10_1155_2024_1317971
crossref_primary_10_1586_17512433_2013_811206
crossref_primary_10_1053_j_ackd_2010_12_001
crossref_primary_10_34067_KID_0001742021
crossref_primary_10_52711_0974_360X_2022_00026
crossref_primary_10_1056_NEJMcpc0804600
crossref_primary_10_2169_naika_112_51
crossref_primary_10_1159_000525561
crossref_primary_10_30895_2312_7821_2020_8_4_198_204
crossref_primary_10_1002_pds_3329
crossref_primary_10_1016_j_revmed_2008_02_001
crossref_primary_10_1097_MD_0000000000022509
crossref_primary_10_1093_ndtplus_sfn093
crossref_primary_10_1136_archdischild_2017_314026
crossref_primary_10_1177_1358863X14568444
crossref_primary_10_34067_KID_0007622021
crossref_primary_10_1007_s00104_011_2173_x
crossref_primary_10_2478_inmed_2020_0140
crossref_primary_10_1097_MD_0000000000003363
crossref_primary_10_2169_naika_107_872
crossref_primary_10_1038_sj_ki_5002038
crossref_primary_10_1007_s40620_016_0309_2
crossref_primary_10_1016_j_cegh_2017_12_008
crossref_primary_10_1038_s41598_023_48430_9
crossref_primary_10_1111_nep_12226
crossref_primary_10_1681_ASN_2016020192
crossref_primary_10_1016_j_drudis_2009_03_014
crossref_primary_10_1007_s40264_022_01181_4
crossref_primary_10_4068_cmj_2023_59_2_115
crossref_primary_10_4103_ijn_IJN_397_20
crossref_primary_10_1016_j_kint_2022_06_007
crossref_primary_10_32818_reccmi_a6n3a5
crossref_primary_10_3892_etm_2018_6088
crossref_primary_10_1007_s11255_011_9972_3
crossref_primary_10_1053_j_ackd_2016_11_016
crossref_primary_10_1186_1471_2369_14_150
crossref_primary_10_3389_fphar_2022_957980
crossref_primary_10_1093_ckj_sfz097
crossref_primary_10_1097_SMJ_0b013e3181f6539d
crossref_primary_10_1111_j_1365_2125_2010_03623_x
crossref_primary_10_1161_CIRCULATIONAHA_113_003602
crossref_primary_10_15171_npj_2017_02
Cites_doi 10.1093/ndt/gfh137
10.1111/j.1572-0241.2001.05345.x
10.1345/aph.1D085
10.1093/ndt/gfh485
10.5694/j.1326-5377.2005.tb06675.x
10.1111/j.1440-1797.2005.00365.x
10.1016/0002-9343(92)90181-A
10.1093/ndt/15.9.1450
10.1001/archinte.137.8.997
ContentType Journal Article
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1111/j.1440-1797.2006.00651.x
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1440-1797
EndPage 385
ExternalDocumentID 10_1111_j_1440_1797_2006_00651_x
17014549
NEP651
ark_67375_WNG_TRX236CX_9
Genre article
Journal Article
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1OB
1OC
29M
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAVGM
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABHUG
ABJNI
ABPTK
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADBTR
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFVGU
AFZJQ
AGJLS
AHBTC
AHEFC
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
KMS
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOQ
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
XVB
YFH
ZZTAW
~IA
~WT
AITYG
HGLYW
OIG
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-c4951-4556e8ca00d40d2e6c82494119092292ccd1ffe054b62ca62c8f80eece1f74ce3
IEDL.DBID DR2
ISSN 1320-5358
IngestDate Fri Aug 23 01:58:07 EDT 2024
Thu May 23 23:13:24 EDT 2024
Sat Aug 24 01:00:05 EDT 2024
Wed Jan 17 05:06:04 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4951-4556e8ca00d40d2e6c82494119092292ccd1ffe054b62ca62c8f80eece1f74ce3
Notes ark:/67375/WNG-TRX236CX-9
ArticleID:NEP651
istex:0F38913D54E3BE9355054B5D3D7D3BCA671EAD8A
PMID 17014549
PageCount 5
ParticipantIDs crossref_primary_10_1111_j_1440_1797_2006_00651_x
pubmed_primary_17014549
wiley_primary_10_1111_j_1440_1797_2006_00651_x_NEP651
istex_primary_ark_67375_WNG_TRX236CX_9
PublicationCentury 2000
PublicationDate October 2006
PublicationDateYYYYMMDD 2006-10-01
PublicationDate_xml – month: 10
  year: 2006
  text: October 2006
PublicationDecade 2000
PublicationPlace Melbourne, Australia
PublicationPlace_xml – name: Melbourne, Australia
– name: Australia
PublicationTitle Nephrology (Carlton, Vic.)
PublicationTitleAlternate Nephrology (Carlton)
PublicationYear 2006
Publisher Blackwell Publishing Asia
Publisher_xml – name: Blackwell Publishing Asia
References Clarkson MR, Giblin L, O'Connell FP et al. Acute interstitial nephritis: Clinical features and response to corticosteroid therapy. Nephrol. Dial. Transplant. 2004; 19: 2778-83.
Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. Am. J. Gastroenterol. 2001; 96: 3428-31.
Wall CA, Gaffney EF, Mellotte GJ. Hypercalcaemia and acute interstitial nephritis associated with omeprazole therapy. Nephrol. Dial. Transplant. 2000; 15: 1450-52.
Ruffenach SJ, Siskind MS, Lien YH. Acute interstitial nephritis due to omeprazole. Am. J. Med. 1992; 93: 472-3.
Ra A, Tobe SW. Acute interstitial nephritis due to pantoprazole. Ann. Pharmacother. 2004; 38: 41-5.
Geevasinga N, Coleman PL, Roger SD. Rabeprazole-induced acute interstitial nephritis. Nephrology 2005; 10: 7-9.
Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: Experience from a single UK renal unit. Nephrol. Dial. Transplant. 2004; 19: 1441-6.
Petersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
Moore I, Sayer JA, Nayar A et al. Pantoprazole-induced acute interstitial nephritis. J. Nephrol. 2004; 17: 580-81.
Nolan CM, Abernathy RS. Nephropathy associated with methicillin therapy: Prevalence and determinants in patients with staphylococcal bacteraemia. Arch. Intern. Med. 1977; 137: 997-1000.
Geevasinga N, Kairaitis L, Rangan GK et al. Acute interstitial nephritis secondary to esomeprazole. Med. J. Aust. 2005; 182: 235-6.
Delve P, Lau M, Yun K, Walker R. Omeprazole-induced acute interstitial nephritis. N. Z. Med. J. 2003; 116: U332.
National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Quality Initiative. Am. J. Kidney Dis. 2002; 39 (Suppl. 2): S1-246.
2002; 39
1994; 344
2005; 10
2005; 182
1977; 137
2003; 116
2000; 15
2004; 19
2004; 38
2004; 17
1992; 93
2001; 96
17014548 - Nephrology (Carlton). 2006 Oct;11(5):379-80
Petersen TR (e_1_2_6_13_2) 1994; 344
Delve P (e_1_2_6_6_2) 2003; 116
Moore I (e_1_2_6_8_2) 2004; 17
e_1_2_6_7_2
e_1_2_6_9_2
e_1_2_6_4_2
e_1_2_6_3_2
e_1_2_6_5_2
e_1_2_6_12_2
e_1_2_6_2_2
e_1_2_6_10_2
National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board. (e_1_2_6_11_2) 2002; 39
e_1_2_6_14_2
References_xml – volume: 96
  start-page: 3428
  year: 2001
  end-page: 31
  article-title: Acute interstitial nephritis due to omeprazole
  publication-title: Am. J. Gastroenterol.
– volume: 344
  start-page: 1383
  year: 1994
  end-page: 9
  article-title: Randomised trial of cholesterol lowering in patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S)
  publication-title: Lancet
– volume: 38
  start-page: 41
  year: 2004
  end-page: 5
  article-title: Acute interstitial nephritis due to pantoprazole
  publication-title: Ann. Pharmacother.
– volume: 19
  start-page: 1441
  year: 2004
  end-page: 6
  article-title: Drug‐induced tubulo‐interstitial nephritis secondary to proton pump inhibitors: Experience from a single UK renal unit
  publication-title: Nephrol. Dial. Transplant.
– volume: 137
  start-page: 997
  year: 1977
  end-page: 1000
  article-title: Nephropathy associated with methicillin therapy: Prevalence and determinants in patients with staphylococcal bacteraemia
  publication-title: Arch. Intern. Med.
– volume: 116
  start-page: U332
  year: 2003
  article-title: Omeprazole‐induced acute interstitial nephritis
  publication-title: N. Z. Med. J.
– volume: 17
  start-page: 580
  year: 2004
  end-page: 81
  article-title: Pantoprazole‐induced acute interstitial nephritis
  publication-title: J. Nephrol.
– volume: 10
  start-page: 7
  year: 2005
  end-page: 9
  article-title: Rabeprazole‐induced acute interstitial nephritis
  publication-title: Nephrology
– volume: 182
  start-page: 235
  year: 2005
  end-page: 6
  article-title: Acute interstitial nephritis secondary to esomeprazole
  publication-title: Med. J. Aust.
– volume: 15
  start-page: 1450
  year: 2000
  end-page: 52
  article-title: Hypercalcaemia and acute interstitial nephritis associated with omeprazole therapy
  publication-title: Nephrol. Dial. Transplant.
– volume: 19
  start-page: 2778
  year: 2004
  end-page: 83
  article-title: Acute interstitial nephritis: Clinical features and response to corticosteroid therapy
  publication-title: Nephrol. Dial. Transplant.
– volume: 39
  start-page: S1
  issue: Suppl. 2
  year: 2002
  end-page: 246
  article-title: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Quality Initiative
  publication-title: Am. J. Kidney Dis.
– volume: 93
  start-page: 472
  year: 1992
  end-page: 3
  article-title: Acute interstitial nephritis due to omeprazole
  publication-title: Am. J. Med.
– volume: 39
  start-page: S1
  issue: 2
  year: 2002
  ident: e_1_2_6_11_2
  article-title: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Quality Initiative
  publication-title: Am. J. Kidney Dis.
  contributor:
    fullname: National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board.
– volume: 17
  start-page: 580
  year: 2004
  ident: e_1_2_6_8_2
  article-title: Pantoprazole‐induced acute interstitial nephritis
  publication-title: J. Nephrol.
  contributor:
    fullname: Moore I
– ident: e_1_2_6_5_2
  doi: 10.1093/ndt/gfh137
– ident: e_1_2_6_3_2
  doi: 10.1111/j.1572-0241.2001.05345.x
– ident: e_1_2_6_7_2
  doi: 10.1345/aph.1D085
– ident: e_1_2_6_14_2
  doi: 10.1093/ndt/gfh485
– ident: e_1_2_6_10_2
  doi: 10.5694/j.1326-5377.2005.tb06675.x
– ident: e_1_2_6_9_2
  doi: 10.1111/j.1440-1797.2005.00365.x
– volume: 116
  start-page: U332
  year: 2003
  ident: e_1_2_6_6_2
  article-title: Omeprazole‐induced acute interstitial nephritis
  publication-title: N. Z. Med. J.
  contributor:
    fullname: Delve P
– volume: 344
  start-page: 1383
  year: 1994
  ident: e_1_2_6_13_2
  article-title: Randomised trial of cholesterol lowering in patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S)
  publication-title: Lancet
  contributor:
    fullname: Petersen TR
– ident: e_1_2_6_2_2
  doi: 10.1016/0002-9343(92)90181-A
– ident: e_1_2_6_4_2
  doi: 10.1093/ndt/15.9.1450
– ident: e_1_2_6_12_2
  doi: 10.1001/archinte.137.8.997
SSID ssj0017261
Score 2.1698809
Snippet Aim:  Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study...
Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to...
Aim:  Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study...
SourceID crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 381
SubjectTerms 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects
acute interstitial nephritis
Acute Kidney Injury - chemically induced
Acute Kidney Injury - epidemiology
Acute Kidney Injury - pathology
Aged
Aged, 80 and over
Anti-Ulcer Agents - adverse effects
Biopsy
Blood Sedimentation
C-Reactive Protein - metabolism
Enzyme Inhibitors - adverse effects
Female
Humans
Male
Middle Aged
Nephritis, Interstitial - chemically induced
Nephritis, Interstitial - epidemiology
Nephritis, Interstitial - pathology
omeprazole
Omeprazole - adverse effects
pantoprazole
Proton Pump Inhibitors
renal failure
Risk Factors
tubulo-interstitial nephritis
Title Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases
URI https://api.istex.fr/ark:/67375/WNG-TRX236CX-9/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1440-1797.2006.00651.x
https://www.ncbi.nlm.nih.gov/pubmed/17014549
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS8MwEA-iIL74_TG_yIP41tGPJE19E5mKsCGi2LeSJlccg27MDcS_3ru2m1N8EPGhEGhzJcld7nfJ5RfGzkIHEhJAQ3J-7AknI8-YQnhKC-cSECYGWhro9tTtk7hLZdrkP9FZmJofYr7gRpZRzddk4CZ__WbktC8ZJ_FsT0HJoE14knj1CB89zJmk0E2rYHZgWEZSf03q-VHQF0-1Qp3-tuCmFqFs5YuuN9hg1oo6BWXQnk7ytn3_RvD4P83cZOsNZOWXtY5tsSUot9lqt9mU32Hp_XiICJKPUDN4v3zp5326woeb0nFjpxPgxEkxpqQEVHZeAuoPMSld8Br91x825Ch8WPBAcovO9XWXPV13Hq9uvebCBs9inIWxqJQKtDW-74TvQlBWY3QnAgQdSRgmobUuKApAlJir0Bp8dKF9AAtBEQsL0R5bLoclHDAeau1QkPKTyIgCpRKJTITTkSi0BKlaLJgNTjaqeTmyxXhGYBm7jG7ZpLw97LLsrcXOq1GcVzDjAeW1xTJ77t1kjw9pGKmrNEtabL8e5k_RMW2_Cnwjq8H69T-zXuceC4d_rHfE1qo1nyp78JgtT8ZTOEEUNMlPK_3-ADhq9qU
link.rule.ids 315,786,790,1382,27957,27958,46329,46753
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1dS8MwMIiC-uL3x_zMg_jW0Y8kTX0TUefHhsjEvpUsueKYdGNuMPz1XtpubsMHER8KgTZXkrvLfeaOkDPfAIcIkJGMGzrM8MBRKmWOkMyYCJgKwboG6g1Re2H3MY_LdkD2LkxRH2LicLOckZ_XlsGtQ3qOy21gMozCcVBBcK-KCuUScj_P7avnSS0pFNTCG18Z5gGXs2k9P0KakVVLdttHU4JqWpnNpdHNOnkfr6NIQulUh4NWVX_OlXj8p4VukLVSa6WXBZltkgXItshyvYzLb5P4qd9FJZL2kDhoO3trt9q2iw9VmaFKDwdAbVmKvs1LQHqnGSAJ2WJKF7QwAIoPy_ootJtSj1ON8vVjh7zcXDevak7Zs8HRaGqhOcq5AKmV6xrmGh-ElmjgMQ_1jsj3I19r46UpoKLYEr5W-MhUugAavDRkGoJdsph1M9gn1JfSICDhRoFiKUK1dWQCPJFYKjlwUSHeGDtJryjNkUybNAzHuGW20aZN3cMtS0YVcp6jcTJB9Ts2tS3kyWvjNmk-x34gruIkqpC9As_foEMbgWX4hufY-vU_k8b1Ew4O_jjvlKzUmvXH5PGu8XBIVnMXUJ5MeEQWB_0hHKNSNGid5MT-BdSZ-sc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NS-wwEA-iIF6eH8_3XD9zeHjr0qZJmnoTdf1eFlHsrWSTCS4L3WXdBfGvd9J211U8yMNDIdBmSjIzmZnM5BdC_jELAlJARbJhEnAr4kBrxwOpuLUpcJ2A3xq4bcuLB36Viayuf_JnYSp8iNmGm9eMcr32Cj607pOS-7xkkibTnIIUURP9ySUuY-Yl_PRuBiWFdlpG0xPDIhbqY1XPl5Q-mKolP-svc3Zq3pctjVFrlfSnw6hqUPrNybjbNK-fEB5_Zpxr5Ffts9LjSsjWyQIUG2T5ts7K_yZZZzRAF5IOUTRor3jqdXv-Dh-qC0u1mYyBelCKka9KQGmnBaAAeSilI1q5_9WHNToKHTgaCWrQuj5vkofW2f3JRVDf2BAYDLQwGBVCgjI6DC0PLQNpFIZ3PEKvI2UsZcbYyDlAN7ErmdH4KKdCAAORS7iB-A9ZLAYFbBHKlLJISIZprLlDqh5FJsb1iDslQMgGiabMyYcVMEc-H9BwbOOU-Ws2feEeTln-0iCHJRdnHfSo7wvbEpE_ts_z-7uMxfIky9MG-Vux-Z104vOvHN-Iklnf_mfePutgY_s_-x2Q5c5pK7-5bF_vkJVy_6esJNwli-PRBPbQIxp390tRfwPTQfl2
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proton+pump+inhibitors+and+acute+interstitial+nephritis%3A+Report+and+analysis+of+15+cases&rft.jtitle=Nephrology+%28Carlton%2C+Vic.%29&rft.au=SIMPSON%2C+IAN+J&rft.au=MARSHALL%2C+MARK+R&rft.au=PILMORE%2C+HELEN&rft.au=MANLEY%2C+PAUL&rft.date=2006-10-01&rft.pub=Blackwell+Publishing+Asia&rft.issn=1320-5358&rft.eissn=1440-1797&rft.volume=11&rft.issue=5&rft.spage=381&rft.epage=385&rft_id=info:doi/10.1111%2Fj.1440-1797.2006.00651.x&rft.externalDBID=10.1111%252Fj.1440-1797.2006.00651.x&rft.externalDocID=NEP651
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1320-5358&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1320-5358&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1320-5358&client=summon